Cover Image
Market Research Report

China Human Vaccine Industry Report, 2019-2025

Published by ResearchInChina Product code 242708
Published Content info 150 Pages
Delivery time: 1-2 business days
Price
Back to Top
China Human Vaccine Industry Report, 2019-2025
Published: August 21, 2019 Content info: 150 Pages
Description

China has been the world's biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseases to the lowest level.

Following the vaccine scandal of Changsheng Bio-technology Co., Ltd. in 2018, the Vaccine Administration Law of the People's Republic of China was enacted at the Eleventh Meeting of the Standing Committee of the 13th National People's Congress on June 29th, 2019. The Law which is due to take effect on December 1, 2019, will be a boon for better regulation on the whole vaccine market and sound development of the vaccine industry.

The National Institutes for Food and Drug Control approved supply of 276.6 million doses (37 kinds of vaccines) to the market from January to July 2019. Thereof, China National Biotech Group (including Chengdu Institute of Biological Products Co., Ltd., Shanghai Institute of Biological Products Co., Ltd., Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Changchun Institute of Biological Products Co., Ltd. and Changchun Keygen Biological Products Co., Ltd.) boasted the largest lot release volume, or 43.4% of the total, staying far ahead of others as the bellwether in the Chinese vaccine industry.

In China, homemade vaccines lead the market, and the imported take a small share (lower than 5%), especially in the EPI vaccines market which is in the monopoly of local big-name brands. That it takes one year to five years for imported vaccines to acquire the Imported Drug License helps explain why there are just several imported vaccines such as pentavalent vaccine, 13/23-valent pneumococcal vaccine and HPV vaccine available on the Chinese vaccine market.

Chinese vaccine companies have broken the monopoly of their foreign peers on new vaccines like 13-valent pneumococcal vaccine and HPV vaccine, in their race to spend more on research and development. In current stage, Walvax Biotechnology's 13-valent pneumococcal vaccine has been applied for GMP certificate and is expected to be the first approved homemade vaccine of such kind in China in 2019; Beijing Wantai Biological Pharmacy Enterprise's 2-valent HPV vaccine which was applied for launch in November 2017, undergoes the quick review by National Medical Products Administration, and is expected to be the first approved homemade vaccine of such sort in China in 2019.

China's vaccine market will have a rosy prospect. The growing demand for vaccines comes with a large population base, the aging of population, more than 15 million newborns each year and the two-child policy. As people live a better life, they also demand more extra EPI vaccines.

China Human Vaccine Industry Report, 2019-2025 highlights the following:

China's human vaccine industry (environment, status quo, demand, market size, import and export, and competitive pattern);

Chinese human vaccine market segments (demand, lot release volume and competitive pattern);

22 human vaccine companies (operation, vaccine business);

Summary and forecast.

Table of Contents

Table of Contents

1. Overview of Vaccine Industry

  • 1.1 Definition & Classification
  • 1.2 Industry Chain

2. China Human Vaccine Industry

  • 2.1 Operating Environment
    • 2.1.1 International Market
    • 2.1.2 Policy Environment
    • 2.1.3 Biopharmaceutical Market
  • 2.2 Status Quo
  • 2.3 Market Demand
  • 2.4 Circulation Channels
  • 2.5 Market Size
  • 2.6 Import & Export
    • 2.6.1 Import
    • 2.6.2 Export
    • 2.6.3 Average Price
  • 2.7 Competition Pattern

3. Human Vaccine Market Segments in China

  • 3.1 Hepatitis B Vaccine
    • 3.1.1 Demand
    • 3.1.2 Lot Release Volume
    • 3.1.3 Competition Pattern
  • 3.2 Meningococcal Vaccine
    • 3.2.1 Demand
    • 3.2.2 Lot Release Volume
    • 3.2.3 Competition Pattern
    • 3.2.4 Development Prospects
  • 3.3 Hepatitis A Vaccine
    • 3.3.1 Demand
    • 3.3.2 Lot Release Volume
    • 3.3.3 Competition Pattern
  • 3.4 Influenza Vaccine
    • 3.4.1 Demand
    • 3.4.2 Lot Release Volume
    • 3.4.3 Competition Pattern
    • 3.4.4 Development Trend
  • 3.5 Hib Vaccine
    • 3.5.1 Demand
    • 3.5.2 Lot Release Volume
    • 3.5.3 Competition Pattern
    • 3.5.4 Development Trend
  • 3.6 Human Rabies Vaccine
    • 3.6.1 Demand
    • 3.6.2 Lot Release Volume
    • 3.6.3 Competition Pattern
    • 3.6.4 Development Trend
  • 3.7 Varicella Vaccine
    • 3.7.1 Demand
    • 3.7.2 Lot Release Volume
    • 3.7.3 Competition Pattern
    • 3.7.4 Development Trend
  • 3.8 Pneumococcal Vaccines
    • 3.8.1 Demand
    • 3.8.2 Lot Release Volume
    • 3.8.3 Competition Pattern
    • 3.8.4 Development Trend
  • 3.9 DTP Vaccine
    • 3.9.1 Demand
    • 3.9.2 Lot Release Volume
    • 3.9.3 Competition Pattern
    • 3.9.4 Development Trend
  • 3.10 Poliomyelitis Vaccine
    • 3.10.1 Demand
    • 3.10.2 Lot Release Volume
    • 3.10.3 Competition Pattern
    • 3.10.4 Development Trend
  • 3.11 Hepatitis E Vaccine
    • 3.11.1 Demand
    • 3.11.2 Lot Release Volume
    • 3.11.3 Competition Pattern

4. Major Human Vaccine Manufacturers in China

  • 4.1 China National Biotech Group
    • 4.1.1 Profile
    • 4.1.2 National Vaccine & Serum Institute
    • 4.1.3 Chengdu Institute of Biological Products Co., Ltd.
    • 4.1.4 Shanghai Institute of Biological Products Co., Ltd.
    • 4.1.5 Wuhan Institute of Biological Products Co., Ltd.
    • 4.1.6 Lanzhou Institute of Biological Products Co., Ltd.
    • 4.1.7 Changchun Institute of Biological Products Co., Ltd.
    • 4.1.8 Changchun Keygen Biological Products Co., Ltd.
  • 4.2 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
    • 4.2.1 Profile
    • 4.2.2 Operation
    • 4.2.3 Revenue Structure
    • 4.2.4 R&D and Investment
    • 4.2.5 Production and Sales
    • 4.2.6 Vaccine Business
    • 4.2.7 Development Strategy
  • 4.3 Hualan Biological Engineering Inc.
    • 4.3.1 Profile
    • 4.3.2 Operation
    • 4.3.3 Revenue Structure
    • 4.3.4 R&D
    • 4.3.5 Vaccine Business
    • 4.3.6 Development Strategy
  • 4.4 Chongqing Zhifei Biological Products Co., Ltd.
    • 4.4.1 Profile
    • 4.4.2 Operation
    • 4.4.3 Revenue Structure
    • 4.4.4 Gross Margin
    • 4.4.5 R&D
    • 4.4.6 Development Dynamics
    • 4.4.7 Development Strategy
  • 4.5 Walvax Biotechnology Co, Ltd.
    • 4.5.1 Profile
    • 4.5.2 Operation
    • 4.5.3 Revenue Structure
    • 4.5.4 Gross Margin
    • 4.5.5 R&D
    • 4.5.6 Vaccine Business
    • 4.5.7 Development Trend
  • 4.6 Liaoning Cheng Da Co., Ltd.
    • 4.6.1 Profile
    • 4.6.2 Operation
    • 4.6.3 Revenue Structure
    • 4.6.4 Gross Margin
    • 4.6.5 Major Customers
    • 4.6.6 R&D
    • 4.6.7 Development Strategy
  • 4.7 Shenzhen Kangtai Biological Products Co., Ltd.
    • 4.7.1 Profile
    • 4.7.2 Operation
    • 4.7.3 Revenue Structure
    • 4.7.4 Gross Margin
    • 4.7.5 R&D
    • 4.7.6 Development Strategy
  • 4.8 Changsheng Bio-Technology Co., Ltd.
    • 4.8.1 Profile
    • 4.8.2 Operation
    • 4.8.3 Revenue Structure
    • 4.8.4 R&D
    • 4.8.5 Development Dynamics
  • 4.9 Olymvax Biopharmaceuticals Inc.
    • 4.9.1 Profile
    • 4.9.2 Operation
    • 4.9.3 R&D
  • 4.10 Sinovac Biotech Ltd.
    • 4.10.1 Profile
    • 4.10.2 Operation
    • 4.10.3 Revenue Structure
    • 4.10.4 Sinovac Biotech (Beijing)
  • 4.11 Changchun BCHT Biotechnology Co. Ltd.
    • 4.11.1 Profile
    • 4.11.2 Operation
    • 4.11.3 Development Dynamics
  • 4.12 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
    • 4.12.1 Profile
    • 4.12.2 Operation
  • 4.13 Tibet Amy Biotech & Vaccine Group Co., Ltd.
    • 4.13.1 Profile
    • 4.13.2 Vaccine Business
  • 4.14 NCPC GeneTech Biotechnology Development Co., Ltd.
    • 4.14.1 Profile
    • 4.14.2 Operation
  • 4.15 Dalian Aleph Biomedical Co., Ltd.
    • 4.15.1 Profile
    • 4.15.2 Vaccine Business
  • 4.16 Beijing Minhai Biotechnology Co., Ltd.
    • 4.16.1 Profile
    • 4.16.2 Operation
  • 4.17 CanSino Biologics Inc.
    • 4.17.1 Profile
    • 4.17.2 Operation
    • 4.17.3 R&D and Investment
    • 4.17.4 Development Strategy
  • 4.18 Other Enterprises
    • 4.18.1 Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
    • 4.18.2 Convac Biotechnology Co., Ltd.
    • 4.18.3 Chengdu Kanghua Biological Products Co., Ltd.
    • 4.18.4 Guangzhou Nuocheng Biological Products
    • 4.18.5 CanSino Biologics Inc.

5. Summary and Forecast

  • 5.1 Summary
  • 5.2 Development Trends
    • 5.2.1 Human Vaccine Industry is Increasingly Concentrated
    • 5.2.2 Two-child Policy is in Favor of Human Vaccine Industry Growth
    • 5.2.3 Faster Aging of Population Boosts Human Vaccine Industry
    • 5.2.4 HPV Vaccine Has a Rosy Prospect and Is Expected to Be Localized
    • 5.2.5 Homemade 13-valent Pneumococcal Conjugate Vaccine is Likely to be Launched
    • 5.2.6 Local Companies Invest More Heavily in Research and Development of Vaccine Products Which are Becoming More Various
    • 5.2.7 Demand for Extra EPI Vaccines Is Growing

Selected Charts

  • Vaccine Industry Chain
  • Global Human Vaccine Market Size, 2010-2019
  • Global Human Vaccine Market Size, 2017-2025E
  • Revenue of Major Global Vaccine Companies, 2011-2019
  • Vaccine Sales Growth Rate of Major Global Vaccine Companies, 2012-2019
  • Global Top 5 Vaccines by Sales
  • R&D Pipelines of Global Top 4 Vaccine Giants
  • Gross Industrial Output Value of China Biopharmaceutical Industry, 2008-2019
  • Gross Industrial Output Value of China Biopharmaceutical Industry, 2016-2025E
  • Lot Release Volume of Human Vaccine in China, 2013-2019
  • R&D of Homemade Vaccines of Large Varieties in China
  • China Human Vaccine Market Size, 2010-2019
  • Import Volume and Value of Human Vaccine in China, 2010-2019
  • Export Volume and Value of Human Vaccine in China, 2010-2019
  • Average Unit Export/Import Price of Human Vaccine in China, 2010-2019
  • Stratified Comparison between Local Vaccine Companies in China
  • Comparison of Products and R&D Pipelines between Leading Chinese Vaccine Companies, 2018
  • Lot Release Volume Breakdown of Human Vaccines in China by Nature of Enterprise, 2018
  • Lot Release Volume Breakdown of Human Vaccines in China by Nature of Enterprise, Jan.-Jul.2019
  • Lot Release Volume of Human Vaccines in China by Enterprise, 2018
  • Lot Release Volume of Human Vaccines in China by Enterprise, Jan.-Jul.2019
  • Hepatitis B Morbidity and Mortality in China, 2013-2019
  • Lot Release Volume of Hepatitis B Vaccine in China, 2013-2019
  • Lot Release Volume of Hepatitis B Vaccine in China by Dosage Form, 2013-2019
  • Meningitis Morbidity and Mortality in China, 2013-2019
  • Meningococcal Vaccines Lot Release Volume in China, 2013-2019
  • Meningococcal Vaccines Lot Release Volume in China by Type, 2013-2019
  • Sanofi's Menactra Sales and YoY Growth, 2015-2019
  • GSK's Menveo Sales and YoY Growth, 2015-2019
  • R&D of Epidemic Cerebrospinal Meningitis Conjugate Vaccine in China
  • Hepatitis A Morbidity and Mortality in China, 2013-2019
  • Lot Release Volume of Hepatitis A Vaccine in China, 2013-2019
  • Influenza Morbidity and Mortality in China, 2013-2019
  • H7N9 Influenza Morbidity and Mortality in China, 2013-2019
  • Lot Release Volume of Influenza Vaccine in China, 2013-2019
  • Sanofi's Influenza Vaccine Series Products Sales and YoY Growth, 2012-2019
  • GSK's Influenza Vaccine Series Products Sales and YoY Growth, 2012-2019
  • Free Influenza Vaccination for Targeted Groups in Some Places of China
  • R&D of Quadrivalent Influenza Vaccine in China
  • Lot Release Volume of Hib Vaccine in China, 2013-2019
  • Rabies Morbidity and Mortality in China, 2013-2019
  • Lot Release Volume of Human Rabies Vaccine in China, 2013-2019
  • R&D of Human Rabies Vaccine in China
  • Lot Release Volume of Varicella Vaccine in China, 2013-2019
  • R&D of Varicella Vaccine in China
  • Lot Release Volume of Pneumococcal Vaccines in China, 2013-2019
  • Comparison between Pneumococcal Vaccines Launched on Global Market
  • Global 7/13-valent Pneumococcal Vaccines Sales and YoY Change, 2006-2019
  • Global 23-valent Pneumococcal Vaccine Sales and YoY Change, 2009-2019
  • Key Chinese Companies' Progress in R&D of 13-valent Pneumococcal Vaccine
  • Key Chinese Companies' Progress in R&D of 23-valent Pneumococcal Vaccine
  • Pertussis Morbidity and Mortality in China, 2012-2019
  • Neonatal Tetanus Morbidity and Mortality in China, 2012-2019
  • Lot Release Volume of DTP Vaccine in China, 2013-2019
  • DTcP Vaccines Launched or Being Developed in China
  • Poliomyelitis Morbidity and Mortality in China, 2013-2019
  • R&D of Poliomyelitis Vaccine in China
  • Hepatitis E Morbidity and Mortality in China, 2012-2019
  • Lot Release Volume of Hepatitis E Vaccine in China, 2013-2019
  • Vaccine Varieties of Chengdu Institute of Biological Products
  • Revenue and Net Income of Beijing Wantai Biological Pharmacy Enterprise, 2016-2018
  • Revenue of Beijing Wantai Biological Pharmacy Enterprise by Product, 2016-2018
  • Revenue of Beijing Wantai Biological Pharmacy Enterprise by Region, 2016-2018
  • Beijing Wantai Biological Pharmacy Enterprise's R&D Costs and % of Total Revenue, 2016-2018
  • Beijing Wantai Biological Pharmacy Enterprise's Projects with Funds Raised by IPO
  • Output and Sales of Beijing Wantai Biological Pharmacy Enterprise by Product, 2016-2018
  • Hepatitis E Vaccine Capacity, Output and Capacity Utilization of Beijing Wantai Biological Pharmacy Enterprise, 2016-2018
  • Revenue and Net Income of Hualan Biological Engineering, 2013-2019
  • Revenue Breakdown of Hualan Biological Engineering by Sector, 2013-2018
  • Revenue Structure of Hualan Biological Engineering by Sector, 2013-2018
  • R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2018
  • Output & Sales Volume, Inventory of Hualan Biological Engineering, 2013-2018
  • Vaccine Revenue and Percentage of Hualan Biological Engineering, 2013-2018
  • Gross Margin of Hualan Biological Engineering, 2013-2018
  • Revenue and Net Income of Chongqing Zhifei Biological Products, 2012-2019
  • Gross Margin of Chongqing Zhifei Biological Products by Product, 2013-2018
  • R&D Costs and % of Total Revenue of Chongqing Zhifei Biological Products, 2011-2018
  • Revenue and Net Income of Walvax Biotechnology, 2013-2019
  • Gross Margin of Own Vaccine of Walvax Biotechnology, 2013-2018
  • R&D Costs and % of Total Revenue of Walvax Biotechnology, 2013-2018
  • Progress of Products under Registration Declaration of Walvax Biotechnology, as of 2018
  • Walvax Biotechnology's Timeline of R&D and GMP Application of 13-valent Pneumococcal Vaccine
  • Revenue and Net Income of Liaoning Chengda, 2013-2019
  • Revenue Breakdown of Liaoning Chengda by Product, 2013-2018
  • Revenue Structure of Liaoning Chengda by Product, 2013-2018
  • Gross Margin of Liaoning Chengda, 2013-2018
  • R&D Costs and % of Total Revenue of Liaoning Chengda, 2014-2018
  • Revenue and Net Income of Shenzhen Kangtai Biological Products, 2013-2019
  • Gross Margin of Shenzhen Kangtai Biological Products, 2013-2018
  • R&D Costs and % of Total Revenue of Shenzhen Kangtai Biological Products, 2013-2018
  • Revenue and Net Income of Changsheng Bio-technology, 2014-2018
  • Revenue Breakdown of Changsheng Bio-technology by Product, 2014-2018
  • Revenue Structure of Changsheng Bio-technology by Product, 2014-2018
  • R&D Costs and % of Total Revenue of Changsheng Bio-technology, 2014-2018
  • Revenue and Net Income of Olymvax Biopharmaceuticals, 2014-2019
  • Main Products of Sinovac Biotech
  • Revenue and Net Income of Sinovac Biotech, 2013-2019
  • Financial Indices of Sinovac Biotech, 2015-2018
  • Financial Indices of Changchun BCHT Biotechnology, 2014-2019
  • Equity Structure of Zhejiang Tianyuan Bio-Pharmaceutical
  • Revenue and Net Income of Zhejiang Tianyuan Bio-Pharmaceutical, 2013-2016
  • Financial Indices of NCPC GeneTech Biotechnology Development, 2014-2018
  • Development History of CanSino Biologics
  • Consolidated Income of CanSino Biologics, 2016-2018
  • R&D Expenditure of CanSino Biologics, 2016-2018
  • R&D Pipelines of CanSino Biologics
  • Main Ebola Vaccines Being Developed Worldwide
  • Main Partners of CanSino Biologics
  • Products Being Researched by CanSino Biologics
  • China's Vaccine Market Size, 2017-2025E
  • Number of Newborns in China, 2015-2025E
  • China's Population Aged over 60 and % of Total Population, 2009-2018
  • Global Incidence of Cervical Cancer
  • Global 4/9-valent HPV Vaccines Sales and YoY Change (Merck Sharp & Dohme), 2009-2019
  • Global 2-valent HPV Vaccine Sales and YoY Change (GSK), 2008-2019
  • List of Countries Bringing HPV Vaccine into Vaccination Program (Those in Green Having Done This)
  • R&D Investment of Major Vaccine Companies in China, 2013-2018
  • Comparison between EPI Vaccine and Extra EPI Vaccine in China
  • Prices of Extra EPI Vaccines in China
  • Extra EPI Vaccines Paid by Medical Insurance and Financial Subsidy Policies in China by Region
  • Classification of Vaccines
  • Main Mergers & Acquisitions in the Vaccine Industry Worldwide, 2005-2019
  • Related Policies in China Human Vaccine Industry, 2006-2019
  • EPI Human Vaccine Varieties in China
  • Top10 Human Vaccines by Lot Release Volume in China, 2018-2019
  • Main Human Vaccine Varieties and Producers Granted Permit for Lot Release in China, Jan.-Jul. 2019
  • China's Human Vaccine Import Volume and Value by Country, 2018
  • Top 10 Countries/Regions of China Human Vaccine Export, 2018
  • Human Vaccine Lot Release Volume of Major Vaccine Enterprises in China, 2014-2019
  • Vaccine Revenue of Major Human Vaccine Enterprises in China, 2013-2019
  • Hepatitis B Morbidity and Mortality in China, Jan-Jun 2019
  • Lot Release Volume of Major Hepatitis B Vaccine Companies in China, 2013-2019
  • Share of Major Hepatitis B Vaccine Companies by Lot Release Volume in China, 2013-2019
  • Meningitis Morbidity and Mortality in China, Jan.-Jun. 2019
  • Lot Release Volume of Major Meningococcal Vaccines Companies in China, 2013-2019
  • Share of Major Meningococcal Vaccines Companies by Lot Release Volume in China, 2013-2019
  • Hepatitis A Morbidity and Mortality in China, Jan.-Jun. 2019
  • Lot Release Volume of Major Hepatitis A Vaccine Companies in China, 2013-2019
  • Share of Major Hepatitis A Vaccine Companies by Lot Release Volume in China, 2013-2019
  • Influenza Morbidity and Mortality in China, Jan.-Jun. 2019
  • H7N9 Influenza Morbidity and Mortality in China, Jan.-Jun. 2019
  • Lot Release Volume of Major Influenza Vaccine Companies in China, 2013-2019
  • Share of Major Influenza Vaccine Companies by Lot Release Volume in China, 2013-2019
  • Lot Release Volume of Major Hib Vaccine Companies in China, 2013-2019
  • Share of Major Hib Vaccine Companies by Lot Release Volume in China, 2013-2019
  • Rabies Morbidity and Mortality in China, Jan.-Jun. 2019
  • Lot Release Volume of Major Human Rabies Vaccine Companies in China, 2013-2019
  • Share of Major Human Rabies Vaccine Companies by Lot Release Volume in China, 2013-2019
  • Lot Release Volume of Major Varicella Vaccine Companies in China, 2013-2019
  • Share of Major Varicella Vaccine Companies by Lot Release Volume in China, 2013-2019
  • Lot Release Volume of Major Pneumococcal Vaccines Companies in China, 2013-2019
  • Share of Major Pneumococcal Vaccine Companies by Lot Release Volume in China, 2013-2019
  • Pertussis Morbidity and Mortality in China, Jan.-Jun. 2019
  • Neonatal Tetanus Morbidity and Mortality in China, Jan.-Jun. 2019
  • Lot Release Volume of Major DTP Vaccine Companies in China, 2013-2019
  • Share of Major DTP Vaccine Companies by Lot Release Volume in China, 2013-2019
  • Lot Release Volume of Poliomyelitis Vaccine Companies in China, 2013-2019
  • Share of Major Poliomyelitis Vaccine Companies by Lot Release Volume in China, 2013-2019
  • Hepatitis E Morbidity and Mortality in China, Jan.-Jun. 2019
  • Lot Release Volume of Major Hepatitis E Vaccine Companies in China, 2013-2019
  • Specifications and Place of Origin of China National Biotech Group's Main Vaccine Products
  • Vaccine Varieties of Shanghai Institute of Biological Products
  • Operation of Shanghai Institute of Biological Products, 2013-2016
  • Main Products Chongqing Zhifei Biological Products is Selling or Promoting according to Agreements, and Their Purposes
  • Revenue Breakdown of Chongqing Zhifei Biological Products by Product, 2014-2018
  • Lot Release Volume Breakdown of Chongqing Zhifei Biological Products by Product, 2014-2018
  • Revenue Breakdown of Chongqing Zhifei Biological Products by Region, 2014-2018
  • Projects under Registration Process of Chongqing Zhifei Biological Products, as of 2018
  • Progress of Preclinical Projects of Chongqing Zhifei Biological Products by 2018
  • Revenue Breakdown of Walvax Biotechnology by Product, 2014-2018
  • Revenue Breakdown of Walvax Biotechnology by Region, 2014-2018
  • Progress of Walvax Biotechnology's Projects with Raised Fund, as of 2018
  • Output & Sales Volume, Inventory of Walvax Biotechnology, 2014-2018
  • Lot Release Volume of Walvax Biotechnology, 2014-2019
  • Liaoning Chengda's Revenue from Top5 Customers and % of Total Revenue, 2015-2018
  • Main Products and Their Purposes of Shenzhen Kangtai Biological Products
  • Capacity, Output & Sales Volume of Shenzhen Kangtai Biological Products, 2013-2018
  • Revenue Breakdown of Shenzhen Kangtai Biological Products by Product, 2015-2018
  • Lot Release Volume and Percentage of Shenzhen Kangtai Biological Products, 2015-2018
  • Revenue Breakdown of Shenzhen Kangtai Biological Products by Region, 2015-2018
  • Progress of Research Projects of Shenzhen Kangtai Biological Products, as of 2018
  • Major Non-equity Investments by Shenzhen Kangtai Biological Products, as of 2018
  • Output & Sales Volume, Inventory of Changsheng Bio-technology, 2014-2018
  • Progress of Ongoing Projects of Changsheng Bio-technology as of the end of 2018
  • Development Course of Olymvax Biopharmaceuticals
  • Research Progress of Products Developed by Olymvax Biopharmaceuticals
  • Revenue Breakdown of Sinovac Biotech by Product, 2013-2018
  • Equity Structure of Sinovac Biotech
  • Vaccine Products of Zhejiang Tianyuan Bio-Pharmaceutical
  • Equity Structure of Dalian Aleph Biomedical
  • Development Goals of Dalian Aleph Biomedical
  • Financial Indices of Beijing Minhai Biotechnology, 2015-2018
  • Total Assets and Revenue of Shenzhen Sanofi Pasteur Biological Products, 2016
  • HPV Vaccine Products Worldwide
  • Lot Release Volume of HPV Vaccine in China by Enterprise, Jan-Jul 2019
  • Major HPV Vaccine Developers in China and Their Progress
  • Major 13-valent Pneumococcal Conjugate Vaccine Developers in China and Their R&D Progress
  • Main Vaccine Products Being Researched by Companies in China and Their Progress
Back to Top